Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Macro domain containing 2 pseudogene (ENSG00000271608) is annotated as a processed pseudogene—an inactive genomic DNA segment derived from a previously functional gene encoding a macrodomain-containing protein. Pseudogenes arise from gene duplication or retrotransposition events, accumulating mutations that prevent their transcription or translation into functional protein products[2][5]. The macro domain is a ~130–190 amino acid module found in various proteins with roles in ADP-ribose binding, DNA repair, chromatin regulation, and post-translational modification[1][3][4], but in this case, the pseudogene does not encode functional protein. Although pseudogenes may occasionally regulate other genes as competing endogenous RNAs (ceRNAs) or affect microRNA networks[7], there is no evidence that Macro domain containing 2 pseudogene plays an active biological role or represents a therapeutic target. Such entities are generally excluded from drug development pipelines and clinical biomarker lists unless new functionality is experimentally demonstrated.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Macro domain containing 2 pseudogene.